TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer

Company Announcement



Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapy



TIVDAK is the first antibody-drug conjugate in this...

Related Keywords

Miami Beach ,New Jersey ,United States ,Denmark ,Netherlands ,Tokyo ,Japan ,Copenhagen ,Køavn ,American ,Chris Boshoff ,Brian Slomovitz ,Tamika Felder ,Exchange Commission ,American Society Of Clinical Oncology ,Pfizer Inc ,National Cancer Institute ,Drug Administration ,Linkedin ,Gynecologic Oncology Group ,Cervivor Inc ,Pfizer ,Company Announcement ,American Cancer Society ,European Network Of Gynaecological Oncological Trial Groups ,European Society Of Medical Oncology ,Biologics License Application ,Presidential Symposium ,European Society ,Medical Oncology ,Gynecologic Oncology ,Cancer Research Committee ,Mount Sinai Medical Center ,Chief Executive Officer ,Chief Oncology Officer ,Executive Vice President ,Ocular Toxicity ,Important Safety ,Priority Review Designation ,Chief Visionary Officer ,European Network ,Gynaecological Oncological Trial Groups ,Pfizer Oncology ,Genmab Collaboration ,Annual Report ,Y Shaped Genmab ,Looking Information ,Factors That May Affect Future ,Cervical Cancer ,American Society ,Clinical Oncology ,National Cancer ,Stat Facts ,Key Statistics ,American Cancer ,